South Dakota Investment Council Buys New Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

South Dakota Investment Council purchased a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 2,350 shares of the biopharmaceutical company's stock, valued at approximately $1,490,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of REGN. Kestra Private Wealth Services LLC raised its stake in Regeneron Pharmaceuticals by 6.9% during the 1st quarter. Kestra Private Wealth Services LLC now owns 2,058 shares of the biopharmaceutical company's stock worth $1,305,000 after acquiring an additional 132 shares during the period. Balentine LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the first quarter worth $680,000. Private Advisor Group LLC raised its position in shares of Regeneron Pharmaceuticals by 15.9% during the 1st quarter. Private Advisor Group LLC now owns 14,276 shares of the biopharmaceutical company's stock valued at $9,054,000 after purchasing an additional 1,957 shares during the period. Evergreen Wealth Management LLC purchased a new position in shares of Regeneron Pharmaceuticals during the 1st quarter valued at $3,585,000. Finally, Concord Wealth Partners lifted its stake in shares of Regeneron Pharmaceuticals by 58.6% during the 1st quarter. Concord Wealth Partners now owns 2,001 shares of the biopharmaceutical company's stock valued at $1,269,000 after buying an additional 739 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Stock Performance

REGN stock opened at $542.52 on Monday. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $1,211.20. The firm has a market cap of $58.57 billion, a price-to-earnings ratio of 13.81, a PEG ratio of 2.04 and a beta of 0.33. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.03 and a current ratio of 4.93. The firm has a 50-day simple moving average of $544.44 and a two-hundred day simple moving average of $613.61.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). The business had revenue of $3.03 billion for the quarter, compared to analyst estimates of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 15.27% and a net margin of 31.94%. The business's revenue for the quarter was down 3.7% on a year-over-year basis. During the same period in the previous year, the company posted $9.55 earnings per share. On average, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th were paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.65%. The ex-dividend date was Tuesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 8.96%.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on REGN shares. Morgan Stanley cut their price target on Regeneron Pharmaceuticals from $755.00 to $754.00 and set an "overweight" rating for the company in a research note on Thursday, July 10th. Wells Fargo & Company downgraded Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and decreased their target price for the company from $700.00 to $580.00 in a research note on Friday, May 30th. Cantor Fitzgerald initiated coverage on Regeneron Pharmaceuticals in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $695.00 price target for the company. BMO Capital Markets cut their price objective on shares of Regeneron Pharmaceuticals from $800.00 to $600.00 and set an "outperform" rating for the company in a report on Monday, June 2nd. Finally, JPMorgan Chase & Co. lowered their target price on shares of Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating on the stock in a report on Monday, June 9th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, sixteen have issued a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat, Regeneron Pharmaceuticals has a consensus rating of "Moderate Buy" and an average target price of $823.54.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.